Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101937 | 1.00 | EGLN1 (0.40) | EGLN1PTGS1PTGS2AHRTOP1 | |
| SCHEMBL23390257 | 1.00 | EGLN1 (0.40) | EGLN1PTGS1PTGS2AHRTOP1 | |
| SCHEMBL23390113 | 0.92 | PIM1 (0.38) | EGLN1PTGS1PTGS2PIM1CYP11B1 | |
| SCHEMBL29611693 | 0.92 | PIM1 (0.38) | EGLN1PTGS1PTGS2PIM1CYP11B1 | |
| SCHEMBL23390111 | 0.92 | PIM1 (0.38) | EGLN1PTGS1PTGS2PIM1CYP11B1 | |
| SCHEMBL23950645 | 0.92 | EGLN1 (0.39) | EGLN1PTGS1PTGS2AHRTOP1 | |
| SCHEMBL23950999 | 0.91 | PIM1 (0.37) | EGLN1PTGS1PTGS2TOP1PIM1 | |
| SCHEMBL23925586 | 0.91 | EGLN1 (0.39) | EGLN1PTGS1PTGS2AHRTOP1 | |
| SCHEMBL23390306 | 0.91 | CYP2A6 (0.39) | EGLN1PIM1LMNAADORA2AADORA1 | |
| SCHEMBL23390302 | 0.91 | CYP2A6 (0.39) | EGLN1PIM1LMNAADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | claimed |
| WO-2021102288-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2021-05-27 | — | — | WO | claimed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4228649-A1 | BIOMARKERS RELATED TO IMMUNE CHECKPOINT INHIBITOR THERAPY AND METHODS OF USING THE SAME | Senda Biosciences, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| WO-2022081649-A1 | BIOMARKERS RELATED TO IMMUNE CHECKPOINT INHIBITOR THERAPY AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021210970-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021102288-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | EGLN1 38/4885PTGS1 233/4885PTGS2 250/4885 |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | AHR, CD274, ARNT | EGLN1 398/4885PTGS1 3418/4885PTGS2 2926/4885 |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | EGLN1 201/4885PTGS1 487/4885PTGS2 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.